{
    "clinical_study": {
        "@rank": "28284", 
        "arm_group": [
            {
                "arm_group_label": "Probucol 250mg/day", 
                "arm_group_type": "Experimental", 
                "description": "Probucol 250mg group: probucol 250mg 2 tablets, 16 weeks"
            }, 
            {
                "arm_group_label": "Probucol 500mg/day", 
                "arm_group_type": "Experimental", 
                "description": "Probucol 500mg group: probucol 250mg 2 tablets, 16 weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo group: placebo 2 tablets, 16 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is randomized, placebo-controlled, double blind, double dummy, multi-centre\n      trial.\n\n        -  Screening period (4 week)\n\n        -  Double blind treatment period (16 weeks)"
        }, 
        "brief_title": "Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetic Nephropathy", 
        "condition_browse": {
            "mesh_term": [
                "Diabetic Nephropathies", 
                "Kidney Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "1. Usage: 16 week, BID, Prescribed Oral with the breakfast and dinner\n\n        2. Dosage:Placebo group: placebo 2 tablets, 16 weeks Probucol 250mg group: probucol 125mg\n           2 tablets, 16 weeks Probucol 500mg group: probucol 250 mg 2 tablets, 16 weeks"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. The subject is male or female diagnosed with type 2 diabetes mellitus and must be\n             aged 20 to 75 years at the time of screening visit\n\n          2. Urinary albumin excretion > 300 mg/g Cr at screening visit\n\n          3. Subjects administered ACEI or ARB without changing dosage prior to 3 months at the\n             screening visit (if subjects administered ACEI or ARB)\n\n          4. Subjects administered statins without changing dosage prior to 3 months at the\n             screening visit(if subjects administered statins) or subjects have no plan to\n             administered to statin(if subjects is not administered statin)\n\n          5. 15 mL/min \u2264 eGFR \u2264 90 mL min\n\n          6. Subjects must be willing and able to give signed and dated written informed consent.\n\n        Exclusion Criteria:\n\n          1. Type 1 DM or gestational diabetes\n\n          2. Subjects on Renal replacement therapy or Renal transplantation prior to Screening\n             visit\n\n          3. Ventricular arrhythmia (multiple and multifocal premature ventricular contractions)\n\n          4. Cardiac damage (abnormally levels of Troponin I)\n\n          5. Subject with medical history of cardiac syncope or primary syncope\n\n          6. Has condition that may prolong QTc interval (for man QTc interval\uff1e450msec, for woman\n             QTc interval\uff1e470msec) at screening\n\n          7. Pregnant or lactating woman before randomization\n\n          8. Inflammatory bowel disease (ulcerative colitis, Crohn's disease)\n\n          9. Cholestasis\n\n         10. Congestive heart failure\n\n         11. Subjects with a myocardial infarction, Unstable angina, or cerebral infarction within\n             the latest 6 months\n\n         12. Subjects has a diagnosis of NYHA grade III-IV status\n\n         13. AST or ALT is 3.0 times higher than the upper limit of the normal range\n\n         14. Active hepatitis Or Liver cirrhosis\n\n         15. Subjects with Hyperkalemia (K>5.5 mEq/L)\n\n         16. Subjects with Renal Artery stenosis\n\n         17. Subjects with Malignancy within the 5 years at the time of screening visit(except for\n             treated Basal cells carcinoma or squamous cell carcinoma)\n\n         18. Urinary tract disease (urinary tract infection, Neurogenic bladder)\n\n         19. Kidney disease (nephritis, chronic glomerulonephritis or polycystic kidney disease)\n\n         20. Has an allergic history to probucol\n\n         21. HbA1c > 9%\n\n         22. Systolic blood pressure \u2265 160 mmHg or Diastolic blood pressure \u2265 100 mmHg\n\n         23. Subjects taken probucol within 3 months prior to Screening\n\n         24. The subject has received an investigational product or biological agent within 3\n             months prior to screening\n\n         25. Subjects otherwise judged by the investigator or sub investigator to be inappropriate\n             for inclusion in the trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01726816", 
            "org_study_id": "009-KOA-1201i"
        }, 
        "intervention": [
            {
                "arm_group_label": "Probucol 250mg/day", 
                "description": "Probucol 250mg + Placebo", 
                "intervention_name": "Probucol 250mg/day", 
                "intervention_type": "Drug", 
                "other_name": "Probucol 250mg group: probucol 250mg 2 tablets, 16 weeks"
            }, 
            {
                "arm_group_label": "Probucol 500mg/day", 
                "description": "Probucol 500mg + Placebo", 
                "intervention_name": "Probucol 500mg/day", 
                "intervention_type": "Drug", 
                "other_name": "Probucol 500mg group: probucol 250mg 2 tablets, 16 weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Probucol matching placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "placebo 2 tablets, 16 weeks"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Probucol"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Diabetic nephropathy", 
            "Albumin creatinine ratio", 
            "Probucol"
        ], 
        "lastchanged_date": "September 17, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bucheon", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "The Catholic university of Korea, Bucheon St. Mary's Hospital"
                }, 
                "investigator": {
                    "last_name": "SungRae Kim, MD.PhD.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "DaeGu", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Yeungnam University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Hyoung Woo LEE, MD.PhD.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "DaeGu", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Kyungpook National University"
                }, 
                "investigator": {
                    "last_name": "In Kyu Lee, MD.PhD.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "InCheon", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Inha University Hospital"
                }, 
                "investigator": {
                    "last_name": "MoonSuk Nam, MD.PhD.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Incheon", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Gil Hospital"
                }, 
                "investigator": {
                    "last_name": "IeByung Park", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "JeonJu", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Chonbuk national University Hospital"
                }, 
                "investigator": {
                    "last_name": "TaeSon Park, MD.PhD.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Severance Hospital"
                }, 
                "investigator": {
                    "last_name": "Bong Soo Cha, MD.PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Samsumg Medical Center"
                }, 
                "investigator": [
                    {
                        "last_name": "MoonKyu Lee, MD.PhD.", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "JiChul Bae, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "SungHwan Seo, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "SeWon Kim, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "SangMan Chin, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "NaKyung Kim, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Kangbuk Samsung Hospital"
                }, 
                "investigator": {
                    "last_name": "Cheol Young Park, MD.PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Korea University Guro Hospital"
                }, 
                "investigator": {
                    "last_name": "Sei Hyun Baek, MD.PhD.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Kangnam Sacred Hospital"
                }, 
                "investigator": {
                    "last_name": "JaeMyung Yu", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Eulji Hospital"
                }, 
                "investigator": {
                    "last_name": "KyungAh Han", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Kyunghee Univ Hospital at Kangdong"
                }, 
                "investigator": {
                    "last_name": "Yuchul Hwang", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "SungNam", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Seoul National University Bundang Hospital"
                }, 
                "investigator": {
                    "last_name": "Sung-Hee Choi, MD.PhD.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suwon", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "St. Vincent Hospital"
                }, 
                "investigator": {
                    "last_name": "SeungHyun Ko", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "TaeSeo Son, MD.PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Uijeongbu", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "UIJEONGBU ST. MARY's HOSPITAL"
                }, 
                "investigator": {
                    "last_name": "TaeSeo Son, MD.PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase II, Multicenter, Randomized, Double Blind, Double-dummy, 16-week, Placebo Controlled Study to Evaluate the Efficacy and Safety of Probucol in Patients With Nephropathy Due to Type 2 Diabetes.", 
        "other_outcome": [
            {
                "description": "The change in the Total cholesterol from baseline to the end of treatment(16 week)", 
                "measure": "Total Cholesterol", 
                "safety_issue": "No", 
                "time_frame": "16 week"
            }, 
            {
                "description": "The change in the Triglyceride from baseline to the end of treatment(16 week)", 
                "measure": "Triglyceride", 
                "safety_issue": "No", 
                "time_frame": "16 week"
            }, 
            {
                "description": "The change in the LDL-C from baseline to the end of treatment(16 week)", 
                "measure": "LDL-C", 
                "safety_issue": "No", 
                "time_frame": "16 week"
            }, 
            {
                "description": "The change in the HDL-C from baseline to the end of treatment(16 week)", 
                "measure": "HDL-C", 
                "safety_issue": "No", 
                "time_frame": "16 week"
            }, 
            {
                "description": "The change in the oxidized LDL from baseline to the end of treatment(16 week)", 
                "measure": "oxidized LDL", 
                "safety_issue": "No", 
                "time_frame": "16 week"
            }, 
            {
                "description": "The change in the d-ROM from baseline to the end of treatment(16 week)", 
                "measure": "d-ROM", 
                "safety_issue": "No", 
                "time_frame": "16 week"
            }, 
            {
                "description": "The change in the urinary fibronectin from baseline to the end of treatment(16 week)", 
                "measure": "urinary fibronectin", 
                "safety_issue": "No", 
                "time_frame": "16 week"
            }, 
            {
                "description": "The change in the urinary transferrin from baseline to the end of treatment(16 week)", 
                "measure": "urinary transferrin", 
                "safety_issue": "No", 
                "time_frame": "16 week"
            }, 
            {
                "description": "The change in the insulin from baseline to the end of treatment(16 week)", 
                "measure": "insulin", 
                "safety_issue": "No", 
                "time_frame": "16 week"
            }, 
            {
                "description": "The change in the c-peptide from baseline to the end of treatment(16 week)", 
                "measure": "c-peptide", 
                "safety_issue": "No", 
                "time_frame": "16 week"
            }
        ], 
        "overall_contact": {
            "email": "jjnah@otsuka.co.kr", 
            "last_name": "Jaejin Nah"
        }, 
        "overall_contact_backup": {
            "last_name": "Mihwa Kim"
        }, 
        "overall_official": {
            "affiliation": "Samsung Medical Center", 
            "last_name": "MoonKyu Lee, professor", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The change in the A/C ratio from baseline to the end of treatment(16 week) [Time Frame: baseline to 16 weeks]", 
            "measure": "A/C ratio", 
            "safety_issue": "No", 
            "time_frame": "16 week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01726816"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The change in the Serum creatinine from baseline to the end of treatment.", 
                "measure": "Serum creatinine", 
                "safety_issue": "No", 
                "time_frame": "16 week"
            }, 
            {
                "description": "The change in the eGFR from baseline to the end of treatment(16 week)", 
                "measure": "eGFR", 
                "safety_issue": "No", 
                "time_frame": "16 week"
            }, 
            {
                "description": "The change in the cystatin C from baseline to the end of treatment(16 week)", 
                "measure": "cystatin C", 
                "safety_issue": "No", 
                "time_frame": "16 week"
            }, 
            {
                "description": "The change in the urine albumin from baseline to the end of treatment(16 week)", 
                "measure": "urine albumin", 
                "safety_issue": "No", 
                "time_frame": "16 week"
            }, 
            {
                "description": "The change in the P/C ratio from baseline to the end of treatment(16 week)", 
                "measure": "P/C ratio", 
                "safety_issue": "No", 
                "time_frame": "16 week"
            }
        ], 
        "source": "Korea Otsuka Pharmaceutical Co.,Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Korea Otsuka Pharmaceutical Co.,Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}